Study Targeting Myocardial Perfusion and Symptom Relief in Women with SGLT2 Inhibitors (STRONG)
Status:
NOT_YET_RECRUITING
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to that Sodium-glucose cotransporter 2 inhibitors treatment will improve Coronary Microvascular Disease with anginal symptoms associated with non-obstructive coronary disease in women. The main questions it aims to answer are:
Aim 1: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves coronary microvascular disease in women with no evidence of epicardial obstructive coronary artery disease.
Aim 2: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves angina symptoms and other quality of life measurements associated with the improvement of CFR.
AIM 3: Identify the effect of Sodium-glucose cotransporter 2 inhibition on inflammation pathways and markers of systemic Research will compare Dapagliflozin to placebo
Participants will:
* Take study drug or placebo for 12 weeks
* Stress Cardiac magnetic resonance imaging
* 12 lead electrocardiograms
* Complete questionnaires